How Analysts Feel About Adverum Biotechnologies Inc (NASDAQ:ADVM) After Decrease in Sellers?

June 17, 2018 - By Adrian Erickson

The stock of Adverum Biotechnologies Inc (NASDAQ:ADVM) registered a decrease of 9.43% in short interest. ADVM’s total short interest was 2.11M shares in June as published by FINRA. Its down 9.43% from 2.33M shares, reported previously. With 450,800 shares average volume, it will take short sellers 5 days to cover their ADVM’s short positions. The short interest to Adverum Biotechnologies Inc’s float is 8.65%.

It closed at $5.55 lastly. It is down 132.08% since June 17, 2017 and is uptrending. It has outperformed by 119.51% the S&P500.

Adverum Biotechnologies, Inc., a gene therapy company, discovers and develops novel medicines for patients suffering from rare diseases or diseases of eye. The company has market cap of $345.61 million. The firm has a pipeline that includes product candidates to treat wet age-related macular degeneration , alpha 1 antitrypsin deficiency (A1AT), and hereditary angioedema. It currently has negative earnings. The Company’s lead gene therapy programs include ADVM-022 and ADVM-032, which are in the preclinical development of new anti-VEGF gene therapy candidates for wAMD diseases; and ADVM-043, which is in patient enrollment in a phase 1/2 trial for the treatment of A1AT.

More recent Adverum Biotechnologies, Inc. (NASDAQ:ADVM) news were published by: Nasdaq.com which released: “Analysis: Positioning to Benefit within Kinross Gold, New York Mortgage Trust, POSCO, NXP Semiconductors NV …” on June 04, 2018. Also Seekingalpha.com published the news titled: “Adverum: Assessing The Strong Prospects Of A Gene Therapy Innovator” on May 23, 2018. Nasdaq.com‘s news article titled: “Adverum Biotechnologies to Present at the 2018 Jefferies Global Healthcare Conference” with publication date: June 04, 2018 was also an interesting one.

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: